Medullary Thyroid Cancer Clinical Trial
Official title:
Effectiveness of Risk Minimisation Interventions for Vandetanib in Canada
Effectiveness of risk minimisation interventions for vandetanib in Canada
As part of the new drug approval process in Canada, AstraZeneca has committed to Health Canada to conduct a Drug Utilization Study among patients recently treated with CAPRELSA (vandetanib) and a Knowledge and Understanding Survey among the prescribing physicians to determine whether the product monograph, communication plan, and educational material developed by AstraZeneca Canada for vandetanib are adequate to provide knowledge about the potential risks associated with this product, and if other medications taken concomitantly with vandetanib are managed adequately. ;
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03643055 -
18F-Fluorocholine PET/CT in Medullary Thyroid Cancer
|
||
| Terminated |
NCT02709889 -
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06277180 -
68Ga-TCR-FAPI PET/CT Guided Precision Surgery for MTC
|
N/A | |
| Withdrawn |
NCT04760288 -
A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).
|
Phase 3 | |
| Not yet recruiting |
NCT06079723 -
A Detailed Look At What Patients Experience In Medullary Thyroid Cancer Clinical Study
|
||
| Recruiting |
NCT01739634 -
The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03157128 -
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
|
Phase 1/Phase 2 | |
| Completed |
NCT02856347 -
Prospective Study Evaluating the Medullary Thyroid Cancer Management's Care Using PET F-DOPA in Patients With a High Level of Postoperative Residual Thyrocalcitonin
|
N/A | |
| Completed |
NCT03037385 -
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04280081 -
A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation
|
Phase 2 | |
| Not yet recruiting |
NCT06292988 -
Predictive Factors for Medullary Thyroid Cancer Aggressiveness
|
||
| Recruiting |
NCT05830500 -
Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma
|
Phase 4 | |
| Recruiting |
NCT03899792 -
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT01660984 -
Natural History Study of Children and Adults With Medullary Thyroid Cancer
|
||
| Withdrawn |
NCT03838692 -
Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer
|
Phase 2 | |
| Terminated |
NCT02363647 -
Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid or Metastatic Colon Cancer
|
N/A | |
| Terminated |
NCT00582712 -
An Initial Study of Lithium in Patients With Medullary Thyroid Cancer
|
Phase 2 | |
| Recruiting |
NCT06141369 -
Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)
|
N/A | |
| Completed |
NCT06243965 -
Is Desmoplastic Stromal Reaction Useful to Modulate Lymph Node Dissection in Sporadic Medullary Thyroid Carcinoma?
|
||
| Active, not recruiting |
NCT01298323 -
Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment
|
Phase 3 |